Immatics (IMTX) Competitors $4.48 -0.15 (-3.24%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. MIRM, GMTX, EWTX, CNTA, KYMR, CGON, DNLI, BLTE, ARWR, and ARQTShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Kymera Therapeutics (KYMR), CG Oncology (CGON), Denali Therapeutics (DNLI), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Mirum Pharmaceuticals Gemini Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Kymera Therapeutics CG Oncology Denali Therapeutics Belite Bio Arrowhead Pharmaceuticals Arcutis Biotherapeutics Immatics (NASDAQ:IMTX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Which has higher valuation & earnings, IMTX or MIRM? Immatics has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$155.84M3.37-$104.98M$0.1431.39Mirum Pharmaceuticals$336.89M6.42-$163.41M-$1.85-23.85 Do insiders & institutionals have more ownership in IMTX or MIRM? 64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer IMTX or MIRM? Mirum Pharmaceuticals received 102 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 75.00% of users gave Immatics an outperform vote. CompanyUnderperformOutperformImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Mirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Is IMTX or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-47.94% -15.90% -9.38% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Does the media prefer IMTX or MIRM? In the previous week, Immatics had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 13 mentions for Immatics and 9 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.29 beat Immatics' score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, IMTX or MIRM? Immatics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Do analysts rate IMTX or MIRM? Immatics currently has a consensus target price of $16.67, suggesting a potential upside of 279.31%. Mirum Pharmaceuticals has a consensus target price of $58.20, suggesting a potential upside of 31.93%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryImmatics and Mirum Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$529.34M$3.03B$5.63B$7.83BDividend YieldN/A1.55%5.33%4.02%P/E Ratio-6.7231.0023.6718.75Price / Sales3.37431.85380.5990.85Price / CashN/A168.6838.1734.64Price / Book1.533.926.874.23Net Income-$104.98M-$71.95M$3.20B$247.47M7 Day Performance-12.12%-6.83%-3.61%-3.56%1 Month Performance0.32%-12.09%1.46%-5.81%1 Year Performance-58.19%-27.90%9.26%-0.96% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics1.6473 of 5 stars$4.48-3.2%$16.67+272.0%-55.9%$534.72M$155.84M-6.79260Earnings ReportAnalyst RevisionMIRMMirum Pharmaceuticals4.3747 of 5 stars$47.02flat$58.20+23.8%+83.1%$2.30B$336.89M-23.28140News CoveragePositive NewsGMTXGemini TherapeuticsN/A$52.24-1.9%N/A-15.9%$2.26BN/A-52.2430High Trading VolumeEWTXEdgewise Therapeutics1.9186 of 5 stars$23.37-1.0%$45.38+94.2%+27.6%$2.22BN/A-15.5860CNTACentessa Pharmaceuticals3.1003 of 5 stars$16.63+5.6%$26.00+56.3%+29.1%$2.19B$6.85M-10.87200Earnings ReportAnalyst ForecastAnalyst RevisionKYMRKymera Therapeutics1.4007 of 5 stars$33.70+3.6%$56.36+67.2%-26.3%$2.19B$47.07M-14.40170Positive NewsGap DownCGONCG Oncology1.1483 of 5 stars$28.53+5.5%$63.88+123.9%-39.8%$2.17B$684,000.000.0061Earnings ReportAnalyst ForecastDNLIDenali Therapeutics4.3809 of 5 stars$14.76+2.3%$37.20+152.0%-28.0%$2.14B$330.53M-5.35430Positive NewsGap DownBLTEBelite Bio2.1877 of 5 stars$66.94-0.5%$96.33+43.9%+73.8%$2.13BN/A-60.3110ARWRArrowhead Pharmaceuticals3.4263 of 5 stars$15.50+4.7%$41.44+167.4%-51.7%$2.13B$2.50M-3.00400Gap DownARQTArcutis Biotherapeutics2.6749 of 5 stars$17.29+1.6%$18.80+8.7%+58.7%$2.05B$196.54M-9.66150Short Interest ↓Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Mirum Pharmaceuticals Competitors Gemini Therapeutics Competitors Edgewise Therapeutics Competitors Centessa Pharmaceuticals Competitors Kymera Therapeutics Competitors CG Oncology Competitors Denali Therapeutics Competitors Belite Bio Competitors Arrowhead Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMTX Stock Free IMTX Stock Alerts